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volume, individualized to the patient’s disease distribution, to avoid the potentially unnecessary normal tissue exposure
and toxicity risks associated with traditional involved field radiation therapy. The successful implementation of involved
node radiation therapy requires optimal imaging and precise coregistration of baseline imaging with the radiation ther-
apy planning computed tomography scan. Limitations of baseline imaging, changes in patient position, and anatomic
changes after chemotherapy may make this difficult in routine practice. Involved site radiation therapy (ISRT) was intro-
duced by the International Lymphoma Radiation Oncology Group as a slightly larger treated volume, intended to allow
for commonly encountered uncertainties. In addition to imaging considerations, the optimal ISRT treatment volume also
depends on disease histology, stage, nodal or extranodal location, and the type and efficacy of systemic therapy, which in
turn influence the distribution of macroscopic and potential subclinical disease. This article presents a systematic over-
view of ISRT, updating key evidence and highlighting differences in the application of ISRT across the lymphoma clin-
ical spectrum.  2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The involved node radiation therapy (INRT) concept for
early stage Hodgkin lymphoma (ESHL) was introduced by
the European Organisation for Research and Treatment of
Cancer (EORTC) in 2006.1 The intent was to use the
smallest effective treatment volume, individualized to the
patient’s disease distribution, avoiding the potentially un-
necessary normal tissue exposure and toxicity risks asso-
ciated with standard involved field radiation therapy
(IFRT).1,2 For ESHL, the smallest effective volume was
considered to include only disease sites evident at diag-
nosis, assuming the ability of chemotherapy to control
adjacent potential microscopic disease. The efficacy of
INRT for ESHL was subsequently confirmed in a pro-
spective randomized trial.3
To apply this “smallest effective volume” principle more
broadly in lymphoma practice, 2 key considerations needed
to be addressed. First, small irradiated volumes require
optimal imaging for accurate disease localization, as well
as precise coregistration of baseline imaging information
with the RT planning computed tomography (CT).4,5 In
practice, baseline imaging may be suboptimal or difficult to
translate to the planning CT, owing to altered patient po-
sition or anatomic changes after chemotherapy. In 2014, the
International Lymphoma Radiation Oncology Group
(ILROG) introduced involved site radiation therapy (ISRT),
a slightly larger volume intended to allow for these
commonly encountered uncertainties.6
Second, it was recognized that the smallest effective
volume may “look different” in different clinical settings.
Histology, stage, nodal or extranodal location, and the type
and efficacy of systemic therapy all affect the distribution
of macroscopic and potential subclinical disease, which in
turn determine the optimal ISRT volume. ILROG has
published guidelines for ISRT in different clinical settings,and ISRT is internationally recognized as the standard of
care for malignant lymphoma.6-15
The present article provides a systematic overview of
ISRT, updating key evidence and highlighting differences
in the application of ISRT across the lymphoma clinical
spectrum (previous ILROG guidelines may be consulted for
additional details). Commonly encountered challenges in
implementation will be discussed.Imaging Considerations
Accurate contouring requires a thorough clinical assess-
ment, high-quality imaging, and sometimes supplementary
tests (eg, endoscopy).5,16 18-Fluorodeoxyglucose (FDG)
positron emission tomography (PET) is critical for accurate
staging and may modify RT volumes.17-25 PET does not
obviate the need for contrast CT to delineate (for example)
mediastinal lymphadenopathy, or magnetic resonance im-
aging (MRI) to define head and neck involvement. Small-
volume disease not evident on PET may be visible on CT
or MRI.5,16
Imaging uncertainties may be due to the following fac-
tors (Fig. 1):
A. Suboptimal baseline imaging
1. An incomplete study (eg, omitting the neck from a
CT)
2. CT performed without contrast
3. Failure to perform MRI when indicated
4. FDG uptake in brown fat obscuring small-volume
disease
5. Prior steroid exposure compromising PET
interpretation
Fig. 1. Imaging uncertainties: (a) anatomic shifts after chemotherapy (note the shift of the aorta and pulmonary artery); (b)
brown fat potentially obscuring disease; (c) poor anatomic definition with noncontrast computed tomography; (d) ill-defined
extent of pericardial infiltration; (e) uncertainty whether lung is displaced or infiltrated.
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before commencing systemic therapy (eg, repeating a PET
scan after administration of beta-blockers to reduce brown
fat uptake).26
B. Difficult imaging interpretation
1. Equivocal nodes near definite disease sites (eg,
equivocal FDG uptake in nonenlarged nodes)
2. Defining the extent of pleural or pericardial tumor
infiltration
3. Distinguishing organ displacement from infiltration
(eg, lung atelectasis vs tumor infiltration)
4. Heterogeneous FDG avidity.5,18
C. Patient position and set-up
Ideally, baseline imaging is performed in the intended
treatment position to facilitate accurate image fusion.4 This
may not always occur. For example, optimal PET imaging
may require arms to be elevated, whereas treating female
patients with arms down may reduce the volume of breast
tissue in the plane of treatment (Fig. 2).27 Differences in
arm or neck position at baseline and planning CT, and deep
inspiration breath hold may complicate clinical target vol-
ume (CTV) localization (Fig. 3).
D. Anatomic shifts after systemic therapy
After systemic therapy, regression of bulky mediastinal
or abdominal lymphomas may alter the position and shape
of normal structures (Fig. 1a).PET and structural imaging should always be
reviewed with a PET physician/radiologist.18 In the
presence of imaging uncertainties, an additional radial
and craniocaudal expansion may be added to the CTV
to ensure adequate tumor coverage. The expansion
should be determined on an individual case basis after
systematically comparing anatomic landmarks in the
staging and planning scans, correlating baseline tumor
location with the anatomy after systemic therapy.28,29
Determination of the CTV requires clinical judgment
and consideration of radiologic uncertainties and
toxicity risks.6,9,11Benefits and Risks of Reduced Irradiated
Volumes
The shift from mantle RT to IFRT substantially reduced
breast cancer risk.30,31 The shift from IFRT to ISRT is
anticipated to further reduce late toxicity risk, based on
dosimetric and modeling studies.32-43 However, small
treatment volumes are subject to a degree of anatomic
uncertainty, and inadequate tumor coverage may
increase relapse risk.29,44-48 With optimal imaging and
guidelines, the systematic delineation uncertainty
appears to be comparable to that reported in other
tumor types.47 ISRT requires accurate treatment
delivery and verification (Fig. 4).
In every case, adequate tumor coverage must be
balanced against the late toxicity risks of the requisite
Fig. 2. Effect of arm position: (a) baseline positron emission tomography; (b) diagnostic computed tomography; (c)
corresponding levels on planning computed tomography with arms down. Arrows highlight reduced breast volume at relevant
planes.
Fig. 3. Impact of treatment position: (a) altered neck position changes relationship of nodes and pharyngeal soft tissue to
bony landmarks; (b) arm position alters the relationship of cervical and pectoral lymph nodes to bony and soft tissue
landmarks; (c) heart and mediastinal structures in breath-hold (BH) and free-breathing (FB); (d) positron emission tomog-
raphy/computed tomography illustrates blurring and widening of a mediastinal mass in FB.
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Fig. 4. Treatment verification: (a) clinical target volume contours (red arrow) and coronary artery (yellow arrow); (b)
intensity modulated radiation therapy plan showing tight coverage of the involved site radiation therapy volume avoiding
coronary artery; (c) cone beam computed tomography confirms accurate delivery. (A color version of this figure is available
at https://doi.org/10.1016/j.ijrobp.2020.03.019.)
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by the magnitude of benefit anticipated from RT, patient
age (ie, the likelihood of experiencing late toxicity), and
alternative management options, including potential
salvage therapy. Importantly, the toxicity risk reduction
associated with smaller treated volumes depends on tumor
location and patient demography. Small reductions in
mediastinal treatment volumes may significantly reduce
exposure of cardiac substructures, such as the coronary
arteries, whereas small changes in the treated volume in, for
example, the inguinal region of an older patient may only
modestly affect toxicity.
In clinical settings for which published volume and dose
data are limited, the following guidelines may indicate a
range of potentially acceptable volume (or dose) recom-
mendations. In such settings, volume and dose decisions
should reflect uncertainties of disease localization and
toxicity considerations in each case.
RT dose constraints used for common epithelial malig-
nancies are less relevant in the lymphoma setting; the
prescribed doses are often lower than the conventional
constraints, and important late toxicities may occur even
after low doses in long-term survivors. Suggested dose
constraints for patients with mediastinal lymphoma are
shown in Table 1.49 Dose constraints should be applied with
flexibility. Some clinical settings necessitate a treatment
plan that does not meet ideal dose constraints. In settings
where standard dose constraints are easily achieved, furtherplan optimization may be appropriate to keep critical organ
doses as low as reasonably achievable. Ideally, flexible
dose-planning tools will allow optimization of the trade-off
between recurrence risk and late effects risk, and RT plan
optimization and decision analysis tools for lymphomas
continue to be developed.50,51Terminology
The following definitions will be used, reflecting Interna-
tional Commission on Radiation Units guidelines.52,53
Gross tumor volume (GTV): the “gross demonstrable
extent and location of the tumor,” including radiologically
evident (generally PET positive) lesions present at diag-
nosis in patients treated with RT alone. Using combined
modality therapy, the “prechemo” GTV denotes evident
lesions before systemic treatment, whereas the “post-
chemo” GTV denotes radiologically evident or biopsy-
proven disease sites after systemic therapy.
CTV: the GTV and/or a volume containing “subclinical
malignant disease with a certain probability of occurrence
considered relevant for therapy.” For treatment with RT
alone, this volume includes the GTV and adjacent lymph
nodes. For combined-modality therapy, it includes any
“postchemo” GTV as well as the tissue volume that con-
tained initially involved lymph nodes and sites of infiltra-
tive disease (ie, the “prechemo” GTV) that may have
Table 1 Dose and volume considerations
Optimal* Acceptabley If necessaryz Avoid
Heart (89, 145, 146)
Mean (Gy) <5 5-10 10-18 Coronary arteries and left ventricle
V15 <10% 10%-25% 25%-35%
V30 <15% 15%-20%
Lung (147)
V5 <35% 35%-45% 45%-55%
V20 <20% 20%-28% 28%-35%
Mean (Gy) <8 8-12 12-15
Thyroid (148)
V25 <62.5% Whole thyroid
Breast
Mean (Gy) <4 4-15 >15 Glandular tissue
V4 <10% 10%-20% >20%
V10 <10% >10%
* For favorable disease, small-volume early stage lymphoma.
y For bulky mediastinal disease.
z Relapse/refractory disease setting. Adapted with permission from Dabaja et al.49
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after systemic therapy. In specific clinical settings, the CTV
also includes sites considered to be at particular risk based
on knowledge of the natural history and patterns of spread.
Equivocal nodes: lymph nodes near definite disease sites
that are enlarged (>1 cm) but PET negative; normal in size
with equivocal FDG uptake; or present in an increased
number or with asymmetrical distribution. The decision to
include equivocal nodes in the GTV or CTV depends on
clinical context.
The internal target volume (ITV) and planning target
volume (PTV) should be determined according to institu-
tional practice.
Clinical Scenarios
The ISRT volume may be considered in 5 broad clinical
groups:
1. Early stage indolent non-Hodgkin lymphoma (NHL) and
nodular lymphocyte-predominant HL (NLPHL) treated
with RT alone: The CTV includes all evident sites plus
an adequate volume to encompass potential adjacent
subclinical disease.2. ESHL and diffuse large B-cell lymphoma (DLBCL) after
limited systemic therapy: Systemic therapy is highly
likely to control subclinical disease, so the CTV may be
strictly limited to disease sites evident at diagnosis (which
are at highest risk of residual microscopic disease).3. Primary extranodal lymphoma: The CTV is usually the
entire involved organ (with some exceptions) because
extranodal lymphomas often display an infiltrating or
multifocal pattern.4. Advanced stage HL or aggressive NHL after a full
course (typically 6 cycles) of systemic therapy: The CTVincludes any residual GTV plus a subset of disease sites
at elevated risk of harboring subclinical disease after
systemic therapy.5. Relapsed lymphoma undergoing salvage therapy with or
without transplantation: The CTV includes some or all
relapse sites and selected sites of prior disease
involvementEarly stage indolent nodal lymphoma treated
with RT alone
Overview
Historically IFRT was used as sole treatment for localized
follicular lymphoma (FL), nodal marginal zone lymphoma
(MZL), and NLPHL.54-62 Typically, ISRT volumes include
radiologically evident disease sites plus an expansion to
encompass potential adjacent microscopic disease sites.9
Key evidence
Evidence for the efficacy of fields smaller than IFRT for FL
is provided in several publications.54,55,63 Retrospective
studies from Vancouver and Stanford reported excellent
locoregional control using field margins up to 5 cm and 3 to
6 cm, respectively.54,55 Smaller margins are commonly
used in routine practice. Emerging data suggest that similar
treated volumes may also be effective for NLPHL.62-64
Volume
The GTV includes PET-positive nodes and should be
extended to include nearby enlarged or equivocal nodes,
particularly if disease demonstrates low FDG avidity
(Fig. 5).
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including adjacent visible nodes (even if not enlarged). The
CTV may extend to the boundaries of the involved nodal
compartment in the axial plane, aswell as several centimeters in
the craniocaudal plane, depending on radiologic uncertainties
(Fig. 6). For sites in proximity to sensitive structures (eg, sali-
vary glands, breast in younger patients) a minimal CTV
expansion may be used to reduce morbidity risk.
Although not now routine, larger volumes (approximating
IFRT) may be considered when imaging is not optimal.
Dose
For FL, 24 to 30 Gy is recommended, with a randomized
trial suggesting the equivalence of 24 Gy to higher doses
used historically.14,54,55,65-67
For NLPHL, 30 Gy is recommended.60,61,64




The EORTCH10 trial confirmed the efficacy of INRTafter 3
cycles of adriamycin, bleomycin, vinblastine, dacarbazine
(ABVD) for favorable ESHL, with results comparable to
those seenwith the use of IFRT in theRAPID andEORTCH7Fig. 5. Stage I nodular lymphocyte predominant Hodgkin lym
alone: (a) positron emission tomography (PET) positive upper n
ISRT upper neck field; (c) relapse in unirradiated lower neck n
lymphomas treated with radiation therapy alone.trials.3,68,69 INRT (after 4 cycles of ABVD) for unfavorable
ESHL produced a smaller benefit than in the favorable
cohort, with an apparently higher locoregional failure rate.3
After 2 cycles of ABVD for German Hodgkin Study
Group (GHSG) favorable ESHL, IFRT is effective,
although ISRT has not been evaluated in a large prospective
study in this setting.70 It is uncertain whether 2 cycles of
ABVD reliably control subclinical disease in nodes within
an IFRT volume but beyond an ISRT volume. A small US
study provides support for the efficacy of ISRT, with a
reported 4-year RFS of 93%.71
GHSG HD14 utilized IFRT after 2 escalated bleomycin,
etoposide, adriamycin, cyclophosphamide, vincristine, pro-
carbazine, prednisolone (escBEACOPP) plus 2 ABVD for
unfavorable ESHL.72 ISRT is not anticipated to be less
effective in this setting than after 4 ABVD. GHSG HD17
addresses the role of INRT for interim PET-positive patients.
For patients who remained PET positive (Deauville
score 3) after 2 to 3 cycles of ABVD, IFRT produced a
nearly 90% 5-year progression-free survival (PFS) in both
GHSG HD16 and the UK RAPID trials.68,73 For
PET-positive patients (Deauville score 3) after 2 ABVD
in the EORTC H10 trial, INRTwas associated with a 5-year
PFS of 77% and 91% after further ABVD or escBEACOPP,
respectively (most had unfavorable disease).3
Volume
For patients in metabolic complete response (CR) after
chemotherapy, the CTV includes locations of initiallyphoma treated with involved site radiation therapy (ISRT)
eck node and PET negative lower neck node (arrow); (b)
ode. Include equivocal nodes in ISRT volume for indolent
Fig. 6. Stage I follicular lymphoma: gross tumor volume (red) encompasses positron emission tomography positive dis-
ease; CTV (yellow) includes adjacent, positron emission tomography negative nodes (arrows) and extends to anatomic
boundaries. (A color version of this figure is available at https://doi.org/10.1016/j.ijrobp.2020.03.019.)
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systemic therapy (Fig. 7). Widely separated initially
involved sites may be treated separately, and it is not
necessary to irradiate the intervening (initially uninvolved)
tissue.
The CTV reflects the original craniocaudal disease
extent. In the axial plane, the CTV is adjusted for tumor
shrinkage to avoid unnecessary irradiation of initially dis-
placed, uninvolved tissue. If the lymphoma infiltrates an
adjacent organ (typically lung or chest wall), then the
initially infiltrated tissue volume should be included in the
CTV, with consideration of the toxicity implications of the
larger volume.
Contiguous initially equivocal nodes should be consid-
ered for inclusion in the CTV, but the CTV should not be
enlarged to include initially normal nodes.
For GHSG favorable disease, ISRT is increasingly used
after 2 cycles of ABVD. Because data supporting this
practice are still emerging, some authorities use a slightly
more generous ISRT volume (as for indolent lymphoma
treated with RT alone).
For patients who do not achieve a PET CR, the residual
FDG-avid lesion constitutes the “postchemo” GTV. If thislesion occurs within a larger PET-negative mass, the entire
mass evident on CT, along with initially involved sites,
should be included in the CTV.
In this and later sections, it must be emphasized that
patients with residual FDG avidity after systemic therapy
for HL (or DLBCL) require careful multidisciplinary
management. Although selected patients with limited
residual FDG avidity may be treated with RT alone, fit
patients with extensive or progressive FDG-avid sites or
biopsy-proven residual disease commonly proceed to
salvage therapy and stem cell transplantation (see the
ISRT for relapsed/refractory aggressive NHL or HL
section).
Dose
For EORTC favorable ESHL in metabolic CR after 3 to
4 cycles of ABVD, 30 Gy is the standard dose (ESMO
guidelines suggest 20 Gy).3,13,68,72,74 For GHSG favor-
able disease, 20 Gy is standard after 2 cycles of
ABVD.70
For residual PET-positive sites 36 to 40 Gy is recom-
mended. Potential microscopic disease in surrounding
FDG-negative masses (and initial sites in structural CR)
Fig. 7. Stage IIA classical Hodgkin lymphoma in positron emission tomography (PET) remission after 3 cycles of ABVD;
(a) baseline PET, arms elevated; (b) treatment field on planning image, arms down; (c) baseline mediastinal nodes on PET;
postchemotherapy residual mass on (d) contrast computed tomography; (e) planning CT; and (f) clinical target volume
(CTV). Well-defined mediastinal anatomic boundaries allow precise CTV delineation (true involved-node radiation therapy),
with generous supraclavicular CTV expansion allowing for anatomic changes due to altered arm position (involved site
radiation therapy volume).
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IFRT after 3 to 4 cycles of R-CHOP has been an established
strategy for favorable stage I to II DLBCL.75,76 Excellent
results have been reported using modifications of ISRT (ie,
margins of 1-5 cm on the GTV) in both retrospective and
prospective nonrandomized studies.77-83 A study comparing
strict INRT with IFRT showed no difference in outcome.82
Volume
For patients in metabolic CR after chemotherapy, the CTV
includes locations of initially involved nodes, including
sites that have normalized after systemic therapy. Initial
FDG avidity may be heterogeneous, sometimes due to the
presence of necrotic tumor.5 Contiguous nodes that were
enlarged at diagnosis, but with low FDG avidity, should beincluded in the CTV when necrosis is suspected (Fig. 8).
Contiguous initially equivocal nodes should be included in
the CTV, but the CTV should not be enlarged to include
initially normal nodes.
The CTV reflects the original craniocaudal disease
extent. In the axial plane, the CTV is adjusted for tumor
shrinkage to avoid unnecessary irradiation of initially un-
involved tissue displaced by tumor. If the lymphoma in-
filtrates an adjacent organ, the initially infiltrated tissue
volume should be included in the CTV, with consideration
of the toxicity implications of the larger volume.
For patients who do not achieve a PET CR, the residual
FDG-avid lesion constitutes the “postchemo” GTV. If this
lesion occurs within a larger PET-negative mass, the entire
mass evident on CT, along with initially involved sites,
should be included in the CTV.
Dose
Although a wide range of RT doses has been used after R-
CHOP, a randomized trial suggests the equivalence of 30
Gy to higher doses.67,76,83-86 The recommended dose for
Fig. 8. Stage I diffuse large B-cell lymphoma treated with 3 cycles of R-CHOP and involved site radiation therapy: (a)
Coronal positron emission tomography and magnetic resonance imaging demonstrate upper and midneck nodes. Lower right
neck node is nonenlarged and fluorodeoxyglucose negative and excluded from the clinical target volume (CTV); (b) nodal
mass is partly positron emission tomography negative (arrows) with ill-defined boundaries. The CTV includes all initially
suspicious tissue.
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evaluation.83
For low-risk, limited-stage DLBCL treated with 4 to 6
cycles of R-CHOP, limited PET-positive sites identified
after 2 to 4 cycles should receive at least 36 to 40 Gy.76,87,88Unfavorable Stage I to II Mediastinal
Lymphoma: ESHL and Primary Mediastinal
B-cell Lymphoma
Mediastinal lymphomas commonly occur in young pa-
tients for whom late toxicity considerations are important
in determining the optimal use of RT. Although small-
volume upper mediastinal lymphomas may often be
safely irradiated, a bulky mass associated with contig-
uous lower mediastinum disease (Fig. 9a, 9b) or lung or
chest wall infiltration may difficult to irradiate while
respecting dose constraints for heart, lung, and breast
(Table 1).49 If advanced techniques (intensity modulated
RT, volumetric modulated arc therapy, deep inspiration
breath hold, or proton therapy) cannot facilitate the safeirradiation of the entire initial tumor volume, alternative
approaches should be considered.
In such cases, a full course of systemic therapy may
be given, with a “modified ISRT” volume limited to
sites at greatest risk of relapse. Although rigorous
patterns-of-failure data are lacking, many clinicians
determine an ISRT volume based on sites of initial bulk,
slow response (positive interim PET), and the presence
of a residual mass. Potentially, this strategy may confer
some of the benefit of standard ISRT while reducing
normal tissue exposure and toxicity risk. Although it is
assumed that potential small increases in the relapse rate
will be more than offset by reductions in late toxicity,
estimates of toxicity risk reduction are subject to un-
certainty.32,35 In addition, reduced RT-related toxicity
may be offset in part by increasing anthracycline expo-
sure of a full course of chemotherapy.89 Clinical judg-
ment is required to select the optimal treatment strategy
in each case, recognizing these uncertainties; research is
ongoing to develop quantitative methods to optimize
management.
When disease is evenly distributed through multiple
anatomic regions (neck, mediastinum, axillae), a large
Fig. 9. Unfavorable mediastinal lymphoma: bulky site with (a) discrete pericardial deposits or (b) contiguous mass; (c)
widespread evenly distributed disease.
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field (Fig. 9c). In the absence of a bulky mass, or other
features identifying a high-risk subsite, ISRT presents
an “all or none” choice. If a standard ISRT volume
presents a high toxicity risk, chemotherapy alone may
be used.Hodgkin Lymphoma
Key evidence
Six cycles of ABVD produce an approximately 90% 3-
to 5-year PFS for patients with unfavorable ESHL who
are interim PET negative.3,90 Sites at elevated risk of
relapse after systemic therapy may potentially be
identified by initial disease bulk (although total tumorburden is also prognostic), slow response to systemic
therapy, and the presence of a residual PET-negative
mass.90-97
The incremental benefit of radiation after a full course
of systemic therapy is not well quantified. In the EORTC
H10 unfavorable cohort, there were more locoregional
relapses after 6 ABVD alone than after combined mo-
dality therapy with 4 ABVD, supporting the use of
consolidative RT in this setting.3 Randomized studies in
advanced-stage disease report small, nonstatistically sig-
nificant increases in PFS with RT to initial bulky masses
achieving PET CR.98,99
The use of modified ISRT gains some support from the
observation that small-volume disease sites in early PET
complete remission are often controlled by systemic therapy
alone.3,68,93 A small retrospective study of HL treated with
chemotherapy suggested that small cardiophrenic nodes can
Wirth et al. International Journal of Radiation Oncology  Biology  Physics920safely be omitted from the irradiated volume.100 However,
reports of relapses in unirradiated small-volume sites provide
a note of caution.25 There is uncertainty regarding the size and
number of lesions, and the aggregate proportion of the initial
tumor burden, that can be omitted from the ISRT volume
without decreasing tumor control rates.
An alternative to omission of disease sites is the use of a
lower RT dose. Doses of 15 to 24 Gy have been reported to
be effective for initial small-volume sites in morphologic
and metabolic complete response in other clinical set-
tings.70,101-103
Volume
After 6 cycles of ABVD, the minimum ISRT volume
should include residual PET-positive lesions and residual
PET-negative masses (often corresponding to initial bulky
sites; Fig. 10). If this minimum volume cannot be treated
while respecting dose constraints, consider withholding RT.
The CTV should be enlarged to include slowly
responding sites (ie, positive interim PET) and as great a
proportion of initial small-volume disease sites as practi-
cable, without exceeding dose constraints. Isolated, small-
volume sites at a distance from the bulky site may be
excluded from the CTV, if necessary, to respect normal
tissue dose constraints. Alternatively, a single distant car-
diophrenic node may sometimes be safely encompassed inFig. 10. Bulky early stage Hodgkin lymphoma in metabol
chemotherapy positron emission tomography (PET); (b) initially
PET-negative mass; (c) small volume lower mediastinal and peric
Consider irradiating upper mediastinal disease while omitting sma small separate field. If it is necessary to exclude the
majority of the initial aggregate tumor burden to remain
within acceptable dose constraints, consideration should be
given to withholding RT.
The use of less than standard ISRT after 4 or fewer
cycles of ABVD is not recommended.Primary Mediastinal B-Cell Lymphoma
Key evidence
For primary mediastinal B-cell lymphoma, dose adjusted
rituximab, etoposide, prednisolone, vincristine, cyclophos-
phamide, adriamycin appears to be highly effective as
sole therapy, particularly for patients with a metabolic
CR.104-106 R-CHOP chemotherapy is commonly followed
by RT, although the benefit of consolidative RT for patients
in PET CR after chemotherapy is uncertain.107 This ques-
tion was addressed in the recently completed IELSG-37
trial, and results are awaited with interest.108-110
A bulky mass, slow response to systemic therapy, or a
residual mass may predict a higher risk of relapse for
DLBCL.85,111-114 As with HL, the use of modified ISRT
directed to high-risk sites is supported by the ability of
systemic therapy to control small-volume disease sites in
early PET complete remission.76,115ic complete response after 6 ABVD: (a) pre- and post-
bulky upper mediastinal disease with corresponding residual
ardial disease sites in structural and PET complete response.
all-volume pericardial sites to minimize toxicity risk.
Fig. 11. Gastric marginal zone lymphoma with nodal involvement: (a) arrows indicate (i) gastric wall involvement, (ii, iii)
nodal uptake on positron emission tomography, (iv) enlarged positron emission tomography negative node; (b) clinical target
volume (CTV) including whole stomach (yellow) and suspicious adjacent nodes (red), planning target volume (blue), and
intensity modulated radiation therapy plan. (c) Note the greater distance from CTV to heart and breast tissue in breath hold.
(d) Cone beam computed tomography showing variation in stomach shape and position (CTV in yellow). (A color version of
this figure is available at https://doi.org/10.1016/j.ijrobp.2020.03.019.)
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Overview
Primary extranodal lymphomas present great anatomic and
biological variety. They may be multifocal within organs
(macro- or microscopically); may track along organ walls,cavities, and tissue planes; and may be subject to organ
motion and deformability, leading to uncertainty in deter-
mining optimal CTV, ITV, and PTV expansions.11 Two
common categories, MZL and DLBCL, are discussed
below. Readers are referred to previous publications for
reviews of cutaneous lymphomas, nasal NK/T-cell lym-
phoma, and other rare extranodal subtypes.7,11,116
Fig. 11. (Continued).
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Key evidence
For MZL, most published data reflect the results of whole
organ irradiation (eg, stomach, salivary glands, thyroid),
which is the default approach.58,59 For conjunctival MZL,
irradiation confined to the conjunctival sac is highly
effective.11,117 For MZL of the lacrimal gland, recent data
suggest that treatment may be confined to the lacrimal
gland, treating it as a separate organ rather than as part of
the “orbital adnexae” (as done historically). There are
conflicting data on the efficacy of this approach.118,119Volume
The GTV includes PET-positive lesions and PET-positive
adjacent or regional nodes. Supplementary information
from CT, MRI, ultrasound, and endoscopy are especially
important for defining the GTV for MZL considering its
low FDG avidity.
The CTV usually includes the entire involved organ or
compartment: for example, for gastric MZL the whole
stomach is irradiated (Fig. 11). Equivocally involved
adjacent lymph nodes should be included in the CTV. For
MZL limited to the conjunctiva, the entire conjunctival sac
is irradiated with no need to irradiate the whole orbit
(Fig. 12). Partial orbital irradiation may be considered for
MZL of the lacrimal gland with no evidence of diseasebeyond the gland on MRI. Partial organ irradiation may be
considered in other settings where whole organ irradiation
is not feasible or potentially toxic (ie, lung, skin, breast in
young women) on an individual case basis. Image guid-
ance, motion management, and adequate ITV/PTV expan-
sions must be used to account for organ motion and
deformability (Fig. 11c, 11d).
Dose
Currently, 24 to 30 Gy is standard for MZL, with 24 Gy
commonly used for sensitive sites such as the
orbit.59,67,117,120,121 A dose of 4 Gy provides durable local
control in about two-thirds of patients (although less
effective than 24 Gy in a randomized trial) and is being
evaluated for MZL in prospective trials.66,122 A strategy of
using 4 Gy and reserving higher doses for patients not
achieving CR is a very attractive, low-toxicity approach for
sensitive anatomic sites and for patients who are elderly or
at higher than average toxicity risk.
Primary Extranodal DLBCL after 3 to 6 Cycles of
Systemic Therapy
Key evidence
For most primary sites, optimal irradiated volumes have not
been defined in prospective trials. Whole organ irradiation
is the most widely reported approach for many sites (eg,
Fig. 12. Marginal zone lymphoma of the orbit. (a) Conjunctival disease, with clinical target volume (CTV) limited to the
conjunctival sac. (b) Posterior orbital soft tissue mass with CTV including whole orbit.
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which disease is usually multifocal (eg, primary CNS
lymphoma).123
The limitations of imaging in detecting small-volume
disease extensions, together with organ motion and defor-
mation, make partial organ irradiation risky in many
anatomic locations. Partial organ irradiation is appropriate
for unifocal DLBCL involving long bones when disease
extent is well defined on baseline PET and MRI. For
DLBCL of lung and skin, RT is confined to the tissue
volume involved before systemic therapy. Partial organ
irradiation may be considered in selected cases of breast
lymphoma to minimize toxicity risk (Fig. 13).123Volume
For most primary sites, the CTV includes the whole organ/
compartment.
For partial organ irradiation, the CTV includes pre-
chemotherapy involved tissue volume seen on baseline PET
supplemented by CT, MRI, ultrasonography, endoscopy, or
clinical findings, as appropriate. In addition, the limitations
of imaging for some extranodal sites may warrant an
expansion to allow for contouring uncertainties.In special cases prophylactic irradiation of potential
microscopic disease is indicated when there may be a de-
gree of chemoresistance or limited drug access to the vol-
ume at risk.11 For example, for testis lymphoma the CTV
includes the scrotum with contralateral testis.124Dose
The recommended dose is 30 to 36 Gy.ISRT after Full-Dose Systemic Treatment for
Advanced-Stage Aggressive NHL/HL
Overview
There is a lack of uniform practice regarding the use of RT
(and treatment volume) for patients with advanced-stage
lymphomas. After a full course of systemic therapy, RT is
considered for sites potentially at elevated risk of relapse,
such as initially bulky sites. The use of RT is influenced by
the anticipated toxicity of the requisite field and the po-
tential for salvage therapy should the patient relapse.125-127
Fig. 13. (a) Primary breast diffuse large B-cell lymphoma with positive interim positron emission tomography and
metabolic complete response after 6 cycles of R-CHOP; (b) clinical target volume options include residual mass corre-
sponding to the initial fluorodeoxyglucose-avid location adjusted for shrinkage (red), contiguous soft tissue density (yellow),
or the entire breast (green). In this case, the positive interim positron emission tomography led to a more intensive approach,
with whole breast treated to 30 Gy and residual mass treated to 36 Gy. (A color version of this figure is available at https://doi.
org/10.1016/j.ijrobp.2020.03.019.)
Wirth et al. International Journal of Radiation Oncology  Biology  Physics924Advanced DLBCL
Key evidence
The risk of relapse for DLBCL after 6 cycles of R-CHOP
reflects the International Prognostic Index, the initial tumor
bulk (usually defined as a mass >7.5 cm), the rapidity and
completeness of metabolic response, and the presence of a
PET-negative residual mass. The relationship between these
factors and the pattern of failure has not been well studied.
RT may reduce the risk of relapse when given to sites of
initial disease bulk, and potentially to sites exhibiting
slow metabolic response and PET negative residual
masses.84,85,111,113,126-132 RT alone may salvage a propor-
tion of patients with a residual PET-positive site.133Volume
For patients in PET CR, the CTV may include residual
masses (usually corresponding to initially bulky sites) as
well as adjacent, initially involved nodes that have
normalized after chemotherapy to minimize the risk of a
marginal relapse (Fig. 14). This may be influenced by the
bulk of initially involved adjacent sites and the impact of a
larger CTV on potential toxicity.
Residual FDG-positive sites constitute the “postchemo”
GTV. If the PET-positive lesion constitutes part of aresidual mass on CT, the PET-negative residuum should be
included (Fig. 15).
Dose
After PET CR, 30 to 36 Gy is recommended.14,67,84,85,115,129
PET-positive residual masses should receive 36 to 50 Gy.Advanced HL
Key evidence
After ABVD chemotherapy
Historically, adjuvant RT did not benefit patients with
advanced-stage HL in CR on structural imaging after 6
cycles of mechlorethamine, vincristine, procarbazine,
prednisolone, adriamycin, bleomycin, vinblastine (MOPP-
ABV), but it appeared beneficial for patients with residual
masses.134,135 In the PET era, the RATHL trial did not
evaluate RT but failed to demonstrate an adverse impact of
bulky disease for patients who had a negative interim PET
scan.90 In 2 recent Italian trials (GITIL 0607 and FIL
HD0801), consolidative RT to bulky sites (>5 cm) in PET
CR after ABVD chemotherapy was associated with non-
statistically significant increases in PFS of 4% and 7.5%
(intention-to-treat analysis), respectively.98,99 Rapidity of
metabolic response has been used to guide RT use in pe-
diatric patient trials, and a recent analysis of SWOG S0816
ig. 14. (a) Stage IV diffuse large B-cell lymphoma, with bulky abdominal mass (i); partial response on interim
ositron emission tomography (ii); complete response after 6 cycles of R-CHOP (iii). The initially bulky mass was
radiated; (b) the clinical target volume (CTV) (pink) includes posttreatment residua, corresponding to the initial
ass (i, ii); initial conglomerate mass resolved into clusters of enlarged and normal-sized residual nodes post-
hemotherapy (iii, iv). CTV included enlarged (red arrows) and normal-sized residual nodes (yellow arrows). (A
olor version of this figure is available at https://doi.org/10.1016/j.ijrobp.2020.03.019.)






Fig. 15. Stage III diffuse large B-cell lymphoma treated with 6 cycles of R-CHOP: (a) baseline bulky mesenteric mass and
small-volume distant nodes (blue arrows); (b) residual positron emission tomographyepositive node postchemotherapy; (c)
involved site radiation therapy options include residual positron emission tomographyepositive mass (in red) only; initially
involved nodes that remained enlarged on computed tomography (in gray); slightly larger volume encompassing all
contiguous initially involved nodes (blue). Inclusion of the initial bulky disease is recommended, with modifications for
toxicity considerations. (A color version of this figure is available at https://doi.org/10.1016/j.ijrobp.2020.03.019.)
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solidative RT.136,137 This is supported by an unplanned
analysis of the UK RATHL trial, suggesting a benefit from
RT for patients with positive interim PET.97 In current
practice, the use of RT after ABVD for advanced stage HL
is highly selective, based on tumor bulk, response, and
disease distribution.
After BEACOPP chemotherapy
After esc-BEACOPP, RT is effective for patients with re-
sidual FDG-avid masses 2.5 cm in largest diameter.138,139
An adequate ISRT volume should include the contiguous
non-FDGeavid soft tissue mass.48,138Volume
On occasions when RT is given after ABVD chemotherapy,
the CTV includes residual PET-negative masses generally
corresponding to initially bulky sites.
Residual PET-positive sites after ABVD or BEACOPP
constitute the GTV. If the PET-positive lesion is part of a
residual mass, the contiguous PET-negative residuum
should be included in the GTV (Fig. 16).Dose
For sites in metabolic CR, 30 Gy is standard. Residual PET-
positive masses are treated to 36 to 45 Gy.15ISRT for Relapsed/Refractory Aggressive NHL
or HL
Overview
RT is commonly a component of salvage therapy with
systemic treatment, including autologous stem cell trans-
plantation.8,10 RT has an evolving role with new biologic/
immunologic therapies, as bridging therapy (including to
chimeric antigen receptor T cell therapy), as an “immu-
nostimulant,” or for definitive local treatment.140 Salvage
RT may be the sole therapy for limited extent relapse and
for patients who are unable to tolerate aggressive systemic
therapy.141 Salvage strategies are influenced by disease
stage at diagnosis and at relapse/progression, time to first
relapse, histology, and patient fitness for aggressive therapy.
The use of salvage RT requires multidisciplinary discussion
and individualized patient management and is discussed in
detail in recent ILROG publications.8,10
Volume
In salvage settings, tumor control may be prioritized over
toxicity minimization, with potentially larger ISRT volumes.
Limited disease extent at relapse
A relapse of limited anatomic extent may sometimes be
entirely encompassed within a tolerable treatment volume.
Fig. 16. Bulky stage IIBE (lung) Hodgkin lymphoma with residual positron emission tomography (PET) positive lesion
after 6 cycles of esc-BEACOPP: (a) baseline PET; (b) postchemotherapy PET and computed tomography showing residual
PET-positive lesion and surrounding soft tissue mass; (c) involved site radiation therapy volume with gross tumor volume
(red) encompassing residual PET-positive lesion and encompassing adjacent PET-negative residuum (pink); (d) treatment
plan. (A color version of this figure is available at https://doi.org/10.1016/j.ijrobp.2020.03.019.)
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including sites in CR after systemic therapy. Equivocal
nodes adjacent to definite relapse sites should generally be
included in the CTV. If relapse sites are close to sites at
initial diagnosis, consideration may be given to including
the original disease extent in the CTV (Figs. 17, 18). This is
particularly the case with primary treatment failure or early
relapse because a degree of chemoresistance is assumed,
with a consequent higher likelihood of progression within
previously involved sites.142
Sites of active disease after systemic salvage therapy (or
if no systemic therapy is given) constitute the GTV.Widespread relapse
It is usually not feasible to encompass widespread disease
sites in a tolerable ISRT volume. It may be possible to
identify sites at elevated risk of relapse after systemic salvage
therapy, based on bulk at relapse and rapidity and complete-
ness of response to systemic salvage therapy.3,5 For patients
undergoing autologous transplantation, response to cytor-
eduction therapy may predict relapse risk.142
Sites of residual PET-positive disease after systemic
therapy constitute the GTV. PET-negative sites at poten-
tially increased risk of relapse, as well as clinically critical
sites (eg, spinal cord compression, proximal airway
compression), may be considered for inclusion in a CTV.Dose
For patients in metabolic CR after salvage chemo-
therapy and autologous stem cell transplantation,30 Gy for HL and 30 to 36 Gy for DLBCL are
recommended. Higher doses may be considered for
bulky relapse sites, FDG-avid sites after pretransplant
cytoreductive systemic therapy, or residual posttrans-
plant masses.
For residual disease after systemic therapy (or if RT is
the sole salvage therapy) the dose to the GTV is 36 to 45 Gy
for HL and 40 to 55 Gy for DLBCL.Conclusions and Future Directions
The application of ISRT varies across the lymphoma
clinical spectrum and according to the quality and
applicability of available imaging. Emerging data on
patterns of failure after standard treatment will likely
influence the application of ISRT in the future. For
example, the demonstrated efficacy of immunotherapy
or immunochemotherapy for control of systemic dis-
ease in follicular lymphoma may provide increasing
confidence in the use of smaller CTV margins in the
future.65,143 For patients with ESHL, ongoing research
is evaluating whether RT can be limited to residual
anatomic abnormalities after systemic therapy (or
omitted in selected patients).144 If this proves to be the
case, patients may be able to receive effective con-
solidative RT with potentially lower morbidity risk,
particularly for patients with initially extensive medi-
astinal lymphoma.32 As systemic therapy evolves,
particularly with the development of new immuno-
therapies, our approach to defining ISRT will also
certainly evolve.
Fig. 17. Stage II Hodgkin lymphoma with relapse after 6 cycles of ABVD, for posttransplant involved site radiation
therapy: (a, b) different disease distributions at diagnosis and relapse shown on positron emission tomography and planning
computed tomography; (c) digitally reconstructed radiograph showing initial (pink) and relapse sites (blue). (d) Treatment
plan delivering 30 Gy volume to all relapse sites (i). A dose of 20 Gy was given to previously involved sites to reduce
coronary and myocardial exposure (ii). Isolated cardiophrenic node treated with separate electron beam (arrow; iii). (A color
version of this figure is available at https://doi.org/10.1016/j.ijrobp.2020.03.019.)
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Fig. 17. (Continued).
Fig. 18. Relapsed diffuse large B-cell lymphoma for posttransplant radiation therapy: (a) initial tonsillar involvement
(blue) with contiguous/overlapping relapse sites (pink); (b) clinical target volume incorporating both volumes. (A color
version of this figure is available at https://doi.org/10.1016/j.ijrobp.2020.03.019.)
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